Stockreport

Yellowstone Biosciences launches with £16.5 million to pioneer soluble bispecific TCR-based therapies for cancer

Immunocore Holdings plc - American Depositary Shares  (IMCR) 
PDF New oncology company created to unlock a novel class of therapeutics targeting human leukocyte antigen (HLA) Class II expression in a range of common cancersSpun out of [Read more]